Immuno - Resources

Content Type

Subjects

Keywords

Autoimmunity & Immunology

First Patient Dosed with NK Cell Therapy for the Treatment of an Autoimmune Disease, Lupus Nephritis

The NK cell therapy is being trialled in combination with monoclonal antibody therapy and hopes to induce B-cell depletion.

Therapeutic Modalities

Positive Results from iNKT Cell Therapy Clinical Trial for COVID-19 ARDS

The small exploratory trial shows signs that iNKT cells can improve the survival rate of respiratory distress from COVID-19.

Therapeutic Modalities

How to Improve Therapeutic Efficacy: Safety Considerations in Oncolytic Virotherapy

Oncolytic virotherapy targets cancer cells with viruses, promising personalized treatment with minimal side effects. Safety measures include minimizing off-target effects and systemic spread. Combining with immunotherapy enhances efficacy, revolutionizing cancer treatment.

Therapeutic Modalities

Zika Virus Tested as an Effective Oncolytic Agent for Glioblastoma in In Vitro Models

More results are in for the oncolytic potential of the Zika virus, where it has proven effective against the most common form of brain cancer in vitro.

Therapeutic Modalities

Post-Event Proceedings – Immuno 2023

Concise and insightful summaries of presentations delivered by prominent thought leaders at Immuno 2023.

Therapeutic Modalities

In Vivo Models Show Survival Promise for Zika Oncolytic Viral Therapy for Neuroblastoma

One of the deadliest cancers in children could have its survival rate improved by the advent of new research into the oncolytic effect of Zika virus.

Biomarkers in Immuno-Oncology

New Multi-Omic AI-Driven Initiative for Immuno-Oncology Biomarker Development

The team aims to establish a consortium of cancer centres to join the project of developing biomarkers from multi-omic analysis.

Autoimmunity & Immunology

Uncovering Mechanisms of Immunotherapy Response & Resistance with Single Cell & Spatial Multiomics

Discover how 10x Genomics' spatial technologies are revolutionising the study of immunotherapies in solid tumors

Tumour Microenvironment

Decoding the Language of Tumor Immune Microenvironment: A Deep Dive into Spatial Biology Techniques

Immuno by Oxford Global will delve into the fascinating world of spatial biology techniques and their role in decoding the language of the tumour immune microenvironment.

Tumour Microenvironment

Spatial Transcriptomics for Immuno-Oncology and Analysis of the Tumour Microenvironment

An overview of the use of spatial transcriptomics in applications for immuno-oncology and the analysis of the tumour microenvironment.

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.

Therapeutic Modalities

Experiments Link Gut Microbiome and Graft-versus-Host Disease

Modulating the gut microbiome may be a key to preventing GvHD and stopping relapse.

Autoimmunity & Immunology

Balancing Innovation and Ethics: The Role of Regulation in Microbiome-Based Precision Oncology

Microbiome-based precision oncology offers promising cancer treatment possibilities but requires clear regulations due to ethical concerns like patient safety and access. Collaboration among stakeholders is essential to balance innovation and ethics effectively.

Therapeutic Modalities

UPenn Medicine Presents Promising Phase I CAR T Trial with Novel Binding Mechanism

The CAR T therapy targets CD19 closer to the cell membrane and has demonstrated remarkable efficacy in its Phase I clinical trial.

Tumour Microenvironment

Understanding and Overcoming the Immunosuppressive TME

Explore the intricate world of the immunosuppressive tumor microenvironment (TME), a key player in cancer progression and treatment resistance

Biomarkers in Immuno-Oncology

Oncolytic Virus Immunotherapy: A Revolutionary Approach in Immuno-Oncology

Explore the cutting-edge of oncolytic virus immunotherapy in immuno-oncology: the viruses revolutionizing cancer treatment and the promise they hold for future therapies.

Therapeutic Modalities

Immunostimulatory Oncolytic Viruses: Interview with Angelica Loskog, CEO, Lokon Pharma

Diving deep into Lokon Pharma's immunostimulatory oncolytic virus programme. Learn about their LOAd platform, transition to the clinic, and more.

Tumour Microenvironment

The Therapeutic Modulation of Cytokines with Pierre Ferré, VP of Pre-Clinical Development, Compugen

Compugen's candidate therapeutic, COM503, targets interleukin-18 binding protein to unleash interleukin-18's immunostimulatory power.

Tumour Microenvironment

Positive Phase I Data from Oncolytic Virotherapy Trial

TILT-123, an oncolytic virotherapy, has shown promising results from a phase I clinical trial which treats solid tumours in patients that have exhausted other options.

Therapeutic Modalities

Bispecific Antibody Format: Interview with Laura von Schantz, Chief Technology Officer, Alligator Biosciences

Talking with Laura von Schantz, Chief Technology Officer, at Alligator Biosciences about their RUBY bispecific antibody format.

Biomarkers in Immuno-Oncology

Translating the Complex Immune System Into Disease Insights With CyTOF Technology

Reasons to choose CyTOF.

Biomarkers in Immuno-Oncology

NeoGenomics: Connect With Us to Explore How Our Oncology Data and Expertise Can Help Your Team

Data-driven insights from the largest volume cancer-testing lab in the U.S.

Biomarkers in Immuno-Oncology

Expand Access and Simplify Sample Management With Visium CytAssist

Biomarkers in Immuno-Oncology

10x: Single Cell Profiling on More Samples With No Time Constraints

Biomarkers in Immuno-Oncology

Scaling Comparative Lung Cancer Studies Using Chromium Single Cell Gene Expression Flex

Translational & Preclinical Development

Chromium X: the Most Flexible Way to Single Cell

Single cell analysis has been a revolutionary breakthrough in biology. Understanding cellular diversity has enabled significant insights into intracellular mechanisms and their applications to health and disease. But for many researchers, single cell has been out of reach due to technical, cost-per-cell, and scalability challenges.

Translational & Preclinical Development

10x Genomics: Inside Visium Spatial Capture Technology

Visium Spatial Gene Expression incorporates whole transcriptome analysis for intact tissues sections with morphological context. Bringing these complementary methods together offers a previously inaccessible view of tissue biology.

Biomarkers in Immuno-Oncology

TruCulture: A Simple Whole Blood Collection and Culture System for Clinical Immunology Studies

Biomarkers in Immuno-Oncology

Simplify Spatial Imaging Maxpar IMC Cell Segmentation Kit

High-plex imaging starts with robust cell segmentation

Biomarkers in Immuno-Oncology

Bioanalytical Solutions for CAR-T and NK Cell Therapies

Synexa Life Sciences is a bioanalytical and biomarker services laboratory specializing in the development and validation of complex and custom designed assays with progression into clinical trial sample analysis.

Translational & Preclinical Development

Synexa Life Sciences: ProtoTrials®

Enhancing human ex vivo translational outcomes.

Biomarkers in Immuno-Oncology

Synexa Life Sciences: Bioanalytical Solutions for Immuno-oncology Therapeutics

Global leaders in specialist biomarker and bioanalysis research services.

Biomarkers in Immuno-Oncology

Synexa Biomarker and Bioanalytical Solutions

Complex solutions delivered on time and within budget.

Biomarkers in Immuno-Oncology

Rules Based Medicine: Human Services Catalog

Rules-Based Medicine (RBM), a Q2 Solutions Company, is a CLIA-certified immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and products.

Biomarkers in Immuno-Oncology

Rules Based Medicine: Operational Procedures

Rules-Based Medicine (RBM), a Q2 Solutions Company, has spent over 20 years developing and optimizing multiplex immunoassays based on the Luminex xMAP® technology.

Biomarkers in Immuno-Oncology

NeoGenomics: Transforming Care for Cancer Patients

Comprehensive service overview for pharmaceutical partners

Biomarkers in Immuno-Oncology

SyncroPatch 384 For All Your Patch Clamp Needs

Unprecedented flexibility for HTS automated patch clamp.

Biomarkers in Immuno-Oncology

Nanion: Cell Analytics Brochure

Next level live-cell kinetic and phenotypic assays.

Biomarkers in Immuno-Oncology

AtlaZ: Quantitative Live-Cell Analytics

Welcome to the next level of live-cell analytics.

Biomarkers in Immuno-Oncology

Hyperion XTi™ Imaging System

Uniquely designed for clinical research.

Biomarkers in Immuno-Oncology

Immune Cell-mediated Killing of A549 Cancer Target Cells in Real-time

Nanion Technologies GmbH, Munich. TUM, Munich

Therapeutic Modalities

Monitoring Cell – Attachment and Tightjunctions in the Same Assay

Nanion Technologies GmbH, Munich. University of Regensburg, Regensburg.

Therapeutic Modalities

SomaScan Panels

Big Insights. Targeted Data. Consistent Results.

Therapeutic Modalities

SomaScan®Assay v4.1

The SomaScan Platform is a powerful tool with applications in scientific research and health and wellness.

Therapeutic Modalities

SomaSignal® Tests

Multiple clinical assessments from a single blood draw.

Therapeutic Modalities

SomaScan Assay

A proteomics platform driving pioneering discoveries

Therapeutic Modalities

Enfortumab Vedotin/Pembrolizumab Combo Beats Chemo in Phase III Breakthrough

The Phase III clinical trial, named EV-302/KEYNOTE-A39, has unveiled that immunotherapy can outperform chemo in urothelial bladder cancer for the first time.

Translational & Preclinical Development

Handbook for Stem Cell Research

This whitepaper by Sino Biological discusses the different types of stem cells based on their origin and potential, as well as the factors that direct their differentiation toward specific lineages or cell types.

Autoimmunity & Immunology

Cancer Immunotherapy Novel Targets: The Forefront of Immuno-Oncology Research

Cancer Immunotherapy Novel Targets and Immunotherapy are being finely tuned to optimise efficacy and minimise side effects, gradually becoming a standard, perhaps even predominant, method in cancer management.

Therapeutic Modalities

Compugen: Exploring New Pathways and Combinations in Immunotherapy

Looking at new pathways for ICIs and Compugen's triple pathway hypothesis may be paving the way for next-generation cancer immunotherapy.

Navigating the Pharma R&D Regulatory Landscape 2023

Our ‘Navigating the Regulatory Landscape’ eBook has been designed to provide you with invaluable insights into the intricacies of regulations & policies surrounding the challenges and opportunities of Real-World Data, genome editing, biomedical informatics, manufacturing and many more.

Therapeutic Modalities

European Commission Approves Genmab’s Subcutaneous Bispecific Antibody Tepkinly

The approval follows positive results from Genmab's 'Epcore' phase I/II clinical trial.

Immuno-Oncology Vs Chemotherapy: Exploring Treatment Synergies

Unpacking the potential of combining immuno-oncology and chemotherapy: understanding benefits, real-world impact, and addressing concerns.

Tumour Microenvironment

Spotlight on Padmanee Sharma: Conquering Cancer through Resilience and Innovation

Highlighting the exceptional contributions of Padmanee Sharma, whose unyielding determination led her to become a renowned physician and immunologist, reshaping the landscape of cancer research.

Therapeutic Modalities

NK Cell Therapies: Development, Application, and Challenges

Sourcing NK cells, expansion techniques, gene modification, quality control, safety, preservation, and delivery.

Translational & Preclinical Development

iBio Reports Antibody Hat-Trick in its In Vivo IO Programs

Significant progress in iBio's in vivo preclinical programs with positive data from three antibody candidates: anti-EGFRvIII, CCR8, and TROP-2 x CD3.

Biomarkers in Immuno-Oncology

Exploring Oncology Biomarkers in Early Clinical Trials and Precision Medicine: Challenges and Opportunities

The importance of validating hypotheses, understanding the biology of cancer progression, and utilising biomarkers in early screening to stratify populations and improve clinical endpoints.

Translational & Preclinical Development

Using Mouse Models for Preclinical Immuno Oncology

Unveiling advancements in preclinical immuno-oncology: Exploring humanized mouse models and human knock-in mice for targeted cancer therapies.

Therapeutic Modalities

Another Partnership from Takeda and F-Star Therapeutics to Look for Antibody-Based Therapies

The collaboration includes an upfront payment, milestone-dependent funds, and commercial royalties for F-star.

Therapeutic Modalities

Immune Cell Types: Their Opportunities for Therapeutic Use in Oncology

An introduction to the various cell types in the immune system and the opportunities to harness them in immuno-oncology therapies.

Translational & Preclinical Development

Transformative Partnership: Ozette Technologies and Umoja Biopharma Join Forces for Preclinical Studies

The collaboration aims to expand access to immunotherapies and advance the field of CAR T cell therapy.

Therapeutic Modalities

William Coley, the Father of Cancer Immunotherapy and His Legacy

Despite facing criticism in his time, his work laid the foundation for modern immuno-oncology and his legacy continues through the Cancer Research Institute.

Therapeutic Modalities

AstraZeneca and Daiichi Sankyo Share Results of IO Combination Therapy in Ib Clinical Trial

Preliminary results from phase Ib clinical trial, TROPION-Lung02, evaluating the antibody drug conjugate datopotamab deruxtecan in combination with pembrolizumab.

Tumour Microenvironment

T Cell Atlas of Tumour Microenvironment Identifies Previously Unknown Cell State

The atlas provides valuable insights into T cell phenotypic states across various cancer types, paving the way for biomarker discovery and the development of improved therapeutic strategies.

Therapeutic Modalities

Monoclonal Antibodies: Guided Missiles in the Battle Against Cancer and More

Monoclonal antibodies (mAbs) have emerged as highly promising and versatile treatments for various diseases, particularly cancer.

Therapeutic Modalities

Identifying highly potent TNF-?-secreting T cells from blood samples in 7 hours using the Xdrop® double-emulsion droplet-based workflow

Bulk functional assays of immune cells miss highly potent cells within the population. This Xdrop workflow reveals highly potent TNF-?-secreting T cells in a human blood sample.

Therapeutic Modalities

Xdrop® Encapsulate cells, DNA, and more with this benchtop instrument

Xdrop is a unique, user-friendly microfluidics instrument for preparing living mammalian or microbial cells, organelles, DNA, or other biological material for high-resolution downstream analyses.

Therapeutic Modalities

Rapidly quantifying active killer cells using an Xdrop® single-cell format assay based on double-emulsion droplets

Bulk assays of killer cell activity mask the heterogeneity of the individual cells‘ actual cytotoxicity. This Xdrop single-cell format assay for quantifying natural killer cells reveals the active cells and enables their retrieval and expansion.

Therapeutic Modalities

Revealing and retrieving highly potent IFN-? secretors using an Xdrop® single-cell format workflow based on double-emulsion droplets

Bulk functional assays of immune cells miss highly potent cells within the population. This Xdrop single-cell format workflow for IFN-? secretion assessment reveals these highly potent individual cells, enabling their retrieval and expansion.

Therapeutic Modalities

Quantifying individual cells that secrete IFN-?, TNF-?, or both cytokines in a single-cell, drop®-based workflow

This Xdrop workflow enables rapid, multiplex quantification of the individual immune cells in a population that are secreting one or more cytokines. The results for single-cell format multiplex and singleplex assay concurred and were reproducible.

Therapeutic Modalities

Cancer Vaccines: Analysing the Resurgence

Looking at the past, present, and future of cancer vaccines. What are the reasons for past failings? And what's the next step for their development?

Biomarkers in Immuno-Oncology

A ‘New Age’ of Biomarker Technology? Understanding Identification & Validation of IO Biomarkers

Developing and validating IO biomarkers present challenges, such as working with challenging sample types, interpreting sequencing data, and integrating new technologies into the clinic.

Autoimmunity & Immunology

Antibody Therapies to Get Boost from Genmab and Argenx Partnership for Immunology and Oncology

The partnership aims to address unmet patient needs in the areas of immunology and cancer.

Autoimmunity & Immunology

AI Used to Detect Rare Autoimmune Eye Disease

The AI model, called VGG16, analysed CT scans of the eyes of patients and achieved an accuracy of 94.27%.

Therapeutic Modalities

App Note: CAR-T: A Promising Cell Therapy for Cancer Treatment

This application note by Sino Biological explores the key steps involved in CAR-T production to provide insights into the challenges that may impede successful CAR-T therapy.

Therapeutic Modalities

NK Cell Therapies and Their Promising Possibilities

Considering the potential of natural killer (NK) cells as immunotherapies for cancer treatment and the various methods being utilised to overcome cancer cells' resistance to NK cells.

Therapeutic Modalities

Axion Biosystems: In vitro Potency Assays for Immune Cell-Mediated Killing with the Maestro Z

Immunotherapy harnesses the power of the innate and adaptive immune system in various ways to seek out and attack cancer.

Therapeutic Modalities

Axion Biosystems: Quantifying NK-mediated Cytolysis of Glioblastoma in vitro with Maestro Z

Immunotherapy aims to harness and enhance the body’s immune system to fight cancer.

Biomarkers in Immuno-Oncology

Axion Biosystems: Organoid Analysis Module

Robust organoid quantification and monitoring.

Therapeutic Modalities

GD2 CAR-T cells engineered using retroviral transduction or CRISPR editing exhibit strong cytolytic potency against glioma stem cells

Axion BioSystems’ Maestro Z platform offers impedance-based cell analysis for real-time, label-free monitoring of cell viability, morphology, cytolysis, and signaling.

Therapeutic Modalities

Axion Biosystems: Antibody-dependent Cellular Cytotoxicity of Natural Killer Cells

Trastuzumab promotes natural killer cell activation through antibody-dependent cellular cytotoxicity (ADCC).

Therapeutic Modalities

Axion Biosystems: CAR T Cell Potency Assessment with 3D Cancer Spheroid Models

The solid tumor microenvironment poses a significant challenge to immune therapies like CART cells.

Biomarkers in Immuno-Oncology

Volition: Nu.Q Discover

An innovative solution to profiling nucleosomes.

Translational & Preclinical Development

Canopy Biosciences: Using the ROSALIND Platform to Accelerate Single-Cell Data Analysis

Single-Cell RNA-Sequencing CRO Service.

Autoimmunity & Immunology

Canopy Biosciences: nCounter® Host Response Panel for Infectious Disease Research

Understanding the complex relationship between a pathogen and host response is important to developing effective vaccines and therapeutics to fight infectious disease.

Biomarkers in Immuno-Oncology

ChemPartner: GPCR/Transporter/Ion Channel Screening

Overview of Capabilities.

Autoimmunity & Immunology

ChemPartner: Inflammation and Immunology

Specialize in primary immune cells with a full panel of assay format (in vitro and ex vivo) on cells from different species, providing multiple optional readouts.

Translational & Preclinical Development

ChemPartner: Tailored Drug Discovery & Development

ChemPartner has the capabilities and expertise to support the end to end drug discovery process across multiple modalities (illustrated below with the small molecule flow scheme). We support the process with expertise and resources at every stage in a fully managed and integrated manner.

Translational & Preclinical Development

ChemPartner: Nuclear Hormone Receptor Screening

Overview of Capabilities.

Translational & Preclinical Development

ChemPartner: Oncology Pharmacology

Translational & Preclinical Development

ChemPartner: Protein Sciences

Translational & Preclinical Development

ChemPartner: Cancer Cell Line Panel Screening

Leading Cell-Based Assay Service

Translational & Preclinical Development

ChemPartner: Cell Biology

Overview

Translational & Preclinical Development

Functional Evaluation of Unique Anti-PDL1 Antibodies Generated through Single Plasma B Cell Cloning on the Beacon® Platform Versus a Standard Hybridoma Approach

Translational & Preclinical Development

Crown Bioscience: Discover the Infinite Power of Partnership

We are Crown Bioscience and this is where Innovation and Quality Transforms Scientific Discovery

Autoimmunity & Immunology

Novel Targets and Studies in Immunology and Autoimmunity: Antigen-Specific Immunotherapy and Therapeutic Chaperones

Insights on antigen-specific immunotherapy and the immunomodulatory functions of therapeutic chaperones at Immuno UK 2022.

Translational & Preclinical Development

Evaxion Biotech Announce New Source of Immunotherapeutic Targets via AI Platform

ERVs have been strongly associated with overall survival in cancer patients. Evaxion hopes they can act as therapeutic targets for non-responsive immunotherapy patients.

Biomarkers in Immuno-Oncology

Improving Patient Response Through Effective Biomarker Development

Oxford Global's panel discussion brings together expert scientists in the field of immunology and biomarker development.

Therapeutic Modalities

Targeting oxMIF To Develop Novel Biotherapeutics

An interview with Michael Thiele, Chief Scientific Officer, OncoOne Research & Development GmbH.

Therapeutic Modalities

Chipscreen Licences Eucure Biopharma's Keytruda Competitor for Greater China

The investigational bispecific antibody has demonstrated favourable efficacy and safety in preclinical in vivo testing.

Translational & Preclinical Development

Sensei Bio Presents Preclinical Data for Novel Antibody Therapeutic for Solid Tumours

Immuno-oncology company Sensei Bio gave a presentation which outlined convincing preclinical data for their novel antibody therapeutic.

Therapeutic Modalities

Therapy In the Spotlight: CAR T Cell Therapy—Significant Approvals and Regulatory Concerns

What are the regulatory considerations for CAR T cell therapy, and what's next for the approach?

Autoimmunity & Immunology

Exploring the Role of IFNa in Autoimmunity & Infection

On-Demand Webinar featuring Dr Darragh Duffy, LabEx Coordinator at Institut Pasteur

Therapeutic Modalities

Novel TNF Superfamily Antagonists for Cancer & Autoimmunity

An interview with Russell LaMontagne, Co-Founder and Chief Executive Officer, Boston Immune Technologies and Therapeutics

Translational & Preclinical Development

AI-Guided Personalised Cancer Vaccine Designated Fast Track by FDA

Evaxion Biotech uses AI to personalise cancer vaccines for patients’ specific tumours.

Translational & Preclinical Development

Teon Tx and MSD Partner in Oral IO Clinical Trial

Teon Tx and MSD will partner to study a combination of a new immune-modifier and existing anti-PD-1 immune checkpoint inhibitor.

Translational & Preclinical Development

New Funding Given to Network of Experimental Cancer Medicine Centres

The ECMC network will enter new partnerships to increase the availability of clinical trials for cancer patients.

Translational & Preclinical Development

Approaches to Combinational Immunotherapies: From Clinic to Approval

Our panel discussing combination therapeutics addresses challenges, modelling, and the importance of biomarkers.

Therapeutic Modalities

Antibody Discovery by Single B Cell Screening on Beacon®

On-Demand Webinar featuring Dr Amy Sheng, Technical Account Manager at Sino Biological

Therapeutic Modalities

Experts Discuss Developing Oncolytic Virus Immunotherapy

Our November Immuno-Oncology Discussion Group brought together experts in the field of oncolytic virus development to discuss engineering and translational strategies of the field

Therapeutic Modalities

What are the Key Challenges in Developing Bispecific Antibodies for Cancer Immunotherapy?

Are there too many opportunities in antibody-based immunotherapy? How do you choose your targets? How do you know when to kill a project?

Biomarkers in Immuno-Oncology

Enabling Ultrasensitive Protein Quantification with the Quanterix Homebrew Kit

Unique Homebrew Kits give researchers the flexibility to develop custom Simoa assays.

Translational & Preclinical Development

Delivering Immuno-Oncology Therapies for Solid Tumours

The panel at Immuno UK 2022 discuss the unique challenges that come with delivering immunotherapies to solid malignancies.

Therapeutic Modalities

Viral Immunotherapy: A New Approach Towards Tackling Solid Tumours

As an alternative avenue for addressing difficult-to-treat cancers, viral immunotherapies hold significant promise. CAN-2409 is well-tolerated in phase II clinical trials in patients with prostate cancer, and new applications may be on the horizon.

Tumour Microenvironment

Expert Opinions on Targeting the Tumour Microenvironment: Present Challenges and Future Outlook

The tumour microenvironment is a critical target to immuno-oncologists. Our discussion group brings together authorities in targeting the TME.

Oxford Global's R&D Key 40 Stories 2022

Download a copy of the R&D Key 40 Stories 2022 eBook today.

Therapeutic Modalities

T Cell Enhancers: Conditional Activation for a Safe and Durable Response

Crescendo Biologics’ Humabody therapeutic has the potential to address a range of issues which arise when standard monoclonal antibodies target T cell receptors, thanks to their capacity to trigger conditional immune responses.

Autoimmunity & Immunology

Immunology: from Cancer to COVID

Our panel discussion brings together experts in immunology: discussing the key areas of autoimmunity, oncology, and COVID-19.

Translational & Preclinical Development

Sample Storage - MLM Medical Services

Biomarkers in Immuno-Oncology

Autologous Acute Myeloid Leukemia (AML) Platform - Champions Oncology

Translational & Preclinical Development

Western Blot Services - Champions Oncology

Translational & Preclinical Development

Histology and Immunohistochemistry Services - Champions Oncology

Translational & Preclinical Development

Comprehensive T Cell Checkpoint Panel - Champions Oncology

Translational & Preclinical Development

Validated Human Complex Immunophenotyping Panel II - Champions Oncology

Translational & Preclinical Development

Complex Immunophenotyping Panel I - Champions Oncology

Translational & Preclinical Development

Autologous Tumor Infiltrating Lymphocyte (TIL) Platform - Champions Oncology

Translational & Preclinical Development

PhenoSeek AML Flow Cytometry Pane - Champions Oncology

Biomarkers in Immuno-Oncology

TCR-LA Targeting Intracellular Tumour Antigens - Immunitrack

Translational & Preclinical Development

NeoScreen: In Vitro Analysis of Potential Cancer Neo-Epitopes - Immunitrack

Translational & Preclinical Development

Immunohistochemistry Services - Indivumed

Biomarkers in Immuno-Oncology

High-Definition Spatial Proteomics - Ionpath

Translational & Preclinical Development

Safety Lab Services - MLM Medical Labs

Translational & Preclinical Development

Histology Services - MLM Medical Labs

Translational & Preclinical Development

Animal Health - MLM Medical Labs

Therapeutic Modalities

Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape

Synthetic immunity mediated by bispecific T Cell engagers may help to bypass immune escape posed by a lack of appropriate immunotherapeutic target expression. Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments, with the potential to become off-the-shelf therapeutics.

Biomarkers in Immuno-Oncology

TEER with Maestro Z - Axion Biosystems

Translational & Preclinical Development

Virology Studies with Maestro Z - Axion Biosystems

Translational & Preclinical Development

Biognosys Research Services

Therapeutic Modalities

Biologics Solutions: Plasmid DNA - Charles River

Biomarkers in Immuno-Oncology

Cancer Invasion Protocol - CellLink

Translational & Preclinical Development

Developing Tumor Spheroid Protocol - CellLink

Therapeutic Modalities

Biologics Solutions: Viral Vectors - Charles River

Therapeutic Modalities

Biologics Solutions: Cell Therapy - Charles River

Therapeutic Modalities

Biologics Solutions Facilities and Capabilities

Therapeutic Modalities

Immunology Services by Cell Type - Charles River

Biomarkers in Immuno-Oncology

NeXT Personal - Personalis

Biomarkers in Immuno-Oncology

NeXT Liquid Biopsy - Personalis

Biomarkers in Immuno-Oncology

ImmunoID NeXT Cancer Immunogenics Platform - Personalis

Biomarkers in Immuno-Oncology

Assays for Immuno-Oncology Targets - PerkinElmer

Biomarkers in Immuno-Oncology

Immuno-Oncology Drug Discovery - PerkinElmer

Biomarkers in Immuno-Oncology

Bioassays for Biologics - Promega

Biomarkers in Immuno-Oncology

GloMax Multimode Plate Readers - Promega

Biomarkers in Immuno-Oncology

HiBiT Protein Tagging System

Translational & Preclinical Development

Anti-Idiotypic Antibody Production - Rockland

pre

Translational & Preclinical Development

Rockland Custom Services

Translational & Preclinical Development

Host Cell Protein & Bioprocessing Reagent Development - Rockland

Therapeutic Modalities

The Challenges Facing Antibody-Drug Conjugates for Immuno-Oncology

The targeted cancer therapy has made recent clinical and market breakthroughs, but what are the next hurdles for ADCs?

Therapeutic Modalities

Immuno Oncology Investigations: The NKG2D Pathway, Diagnostic Biomarker, and Allogenic CAR Ts

Cell UK 2021 hosts experts in cell and immunotherapy working towards new diagnostic tools and therapies.

Therapeutic Modalities

Express Your Cells: Enhancing T Cell Function with Small Molecule HPK1 Inhibitors

Inhibiting the HPK1 pathway can enhance the cancer killing function of T lymphocytes. RAPT Therapeutics showcases a series of small molecules to do this.

Therapeutic Modalities

iNKT Cells and Their Applications in Immuno-Oncology

The applications of iNKT cells as oncological therapeutics and remedial treatments are almost astoundingly diverse. Their capacity for moderation subject to their intended use makes them suited to a variety of therapeutic functions and applications.

Translational & Preclinical Development

Preclinical Strategies for Combination Immunotherapies

Oncology is almost always oriented towards simultaneous treatment options. We explore why as well as the approach’s unique challenges.

Translational & Preclinical Development

AAV Gene Therapy and CAR T Therapies: Immunogenicity and Immunoassay Development

Dr. Vibha Jawa, Executive Director, Nonclinical Disposition and Bioanalysis at BMS

Therapeutic Modalities

Addressing Immunotherapy Resistance Through PVRIG And TIGIT Blockade

In this interview, Eran Ophir discusses Compugen's exciting approach to immune checkpoint inhibitors for the treatment of cancer and what makes them stand out from the crowd.

Therapeutic Modalities

Using Live Gut Bacteria as a Co-Therapy for Checkpoint Inhibitors

Microbiotica’s live bacterial therapeutic is currently manufacturing for phase Ib trials in 2023.

Therapeutic Modalities

Microbiome Solutions to Immuno-Oncology Problems

Investigating the role of the microbiota in checkpoint inhibitor response.

Translational & Preclinical Development

Investigating the Core Tenet of Immunotherapy: MHC-I Peptide-Receptor Complexes

Axel Ducret, a Roche Senior Principal Scientist, takes us through his work on one of the most important cellular mechanisms in immunotherapy.

Translational & Preclinical Development

The Future of CAR T for Solid Tumours: Antigen Discovery, Persistence, and Fitness

CAR T, the rockstar therapy of immuno-oncology, finds its next big challenge in translating research for use in solid tumours.

Translational & Preclinical Development

Developing Novel Theranostic Approaches for the Development of Oncolytic Viruses

Single-cell, real-time analysis of oncolytic viruses’ efficacy, and replication in living cancer cells.

Autoimmunity & Immunology

Treating Autoimmune Diseases: Past, Present, and Future

Bringing together the experts to discuss the timeline of autoimmune disease therapeutics.

Tumour Microenvironment

Tackling Solid Tumours in Immuno-Oncology

What’s next for CAR T cell therapy? What’s the best way to develop combination therapies for multi-modal efficacy?

Therapeutic Modalities

Targeting Solid Tumours With TCR Guided NK Cells

Video Interview | Namir Hassan, CEO at Zelluna Immunotherapy

Translational & Preclinical Development

Better IO Clinical Trials with ImmunoPET Imaging

Ian A Wilson of ImaginAb delivers the presentation ‘The Value of In Vivo Imaging on the Clinical Development of IO Drugs’ at Oxford Global’s discussion group.

Translational & Preclinical Development

Search and Destroy: Engineering T-Cells to Find and Kill Cancer

Oxford Global’s Immuno Week showcased new ways of reprogramming the immune system to treat malignancy with TCR-T.

Biomarkers in Immuno-Oncology

Three Leading Perspectives on Biomarker Diagnostic Discovery in Immuno-oncology

Early and effective treatment of cancers could mean the difference between life and death. Therefore, companion diagnostics and biomarker discovery could be considered one of the most important avenues to explore in immuno-oncology.

Autoimmunity & Immunology

Insights in Autoimmunity and Immunotherapy

Experts discuss elusively successful therapies and the rising costs that come with new technologies.

Autoimmunity & Immunology

Re-Educating the Immune System: a ‘Brave New World’ in Immunology

RevoloBio’s autoimmunity drug, ‘1805, breaks with the mould in its revolutionary approach. With success in a Phase II clinical trial, scientists wonder what’s around the corner for the field.

Translational & Preclinical Development

Multi-Specific Protein Modalities For Solid Tumours

An interview with Rajika Perera, Chief Executive Officer, Poseidon Laboratory

Therapeutic Modalities

Are Genomic Technologies the Key to Unlock Precision Immunotherapies?

The power of the genome has enormous implications for immunotherapy

Biomarkers in Immuno-Oncology

Perfecting Precision Medicine: The Promise of Biomarkers and Spatial Biology

What is the future of precision medicine for immuno-oncology, and how can we achieve it? In this Insight Article, we sat down with senior representatives from the University of Michigan, the Beth Israel Deaconess Medical Center / Harvard Medical School, and The Institute of Cancer Research, London, to discover more about harnessing the potential of spatial biology and predictive biomarkers to achieve targeted results.

In-Person & Online Events

Online Activities

Speakers

Sponsors

Media Partners

Digital Services

Lead Generation Dinners

Content Services

Event Management

Browse All Resources

Filter by Subject Area

Latest Resources

Resources

Top R&D Stories of 2023